Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Therapy for ARDS in COVID-19
IRCT20200217046526N2Phase 3Completed
- Sponsor
- ACECR
- Start
- Apr 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3 trial of mesenchymal stem cells in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by ACECR. Started Apr 2020; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200217046526N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200217046526N2.